Global Blood Therapeutics with ticker code (GBT) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 68.5 and 60 with a mean TP of 64.5. With the stocks previous close at 68.49 this now indicates there is a potential downside of -5.8%. The 50 day MA is 63.7 and the 200 moving average now moves to 38.56. The market capitalisation for the company is $4,621m. You can visit the company’s website by visiting: https://www.gbt.com
The potential market cap would be $4,352m based on the market concensus.
Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics was incorporated in 2011 and is headquartered in South San Francisco, California.
